BRPI0401908A - Compostos inibidores de serina protease, processo de obtenção e uso para tratamento de flaviviroses - Google Patents

Compostos inibidores de serina protease, processo de obtenção e uso para tratamento de flaviviroses

Info

Publication number
BRPI0401908A
BRPI0401908A BRPI0401908A BRPI0401908A BR PI0401908 A BRPI0401908 A BR PI0401908A BR PI0401908 A BRPI0401908 A BR PI0401908A BR PI0401908 A BRPI0401908 A BR PI0401908A
Authority
BR
Brazil
Prior art keywords
flaviviroses
serine protease
obtaining
treatment
protease inhibitor
Prior art date
Application number
Other languages
English (en)
Inventor
Octavio Augusto Ceva Antunes
Jeronimo Da Silva Costa
Magaly Girao Albuquerque
Ricardo Bicca De Alencastro
Estela Maris Freitas Muri
Marcelo De Lima Bastos
Ricardo Hernandez Valdes
Elaine Fontes Ferreira D Cunha
Marlito Junior Gomes
Original Assignee
Univ Rio De Janeiro
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Rio De Janeiro filed Critical Univ Rio De Janeiro
Priority to BRPI0401908 priority Critical patent/BRPI0401908A/pt
Publication of BRPI0401908A publication Critical patent/BRPI0401908A/pt

Links

Landscapes

  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

"COMPOSTOS INIBIDORES DE SERINA PROTEASE, PROCESSO DE OBTENçãO E USO PARA TRATAMENTO DE FLAVIVIROSES". Refere-se a presente invenção a compostos inibidores de serina protease sintéticos tendo um eixo de simetrica C~ 2~, possuindo na porção central uma estrutura do tipo 1,4:3,6-dianidromanitol e, nas porções laterais, ligações peptidomiméticas com aminoácidos, como por exemplo, lisina (Lis), fenilalanina (Phe), dentre outros, utilizados como base para a preparação de formulações antivirais capazes de cessar a proliferação dos vírus responsáveis pela maioria das flaviviroses, como por exemplo, hepatite C, Dengue e febre do oeste do Nilo.
BRPI0401908 2004-06-04 2004-06-04 Compostos inibidores de serina protease, processo de obtenção e uso para tratamento de flaviviroses BRPI0401908A (pt)

Priority Applications (1)

Application Number Priority Date Filing Date Title
BRPI0401908 BRPI0401908A (pt) 2004-06-04 2004-06-04 Compostos inibidores de serina protease, processo de obtenção e uso para tratamento de flaviviroses

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
BRPI0401908 BRPI0401908A (pt) 2004-06-04 2004-06-04 Compostos inibidores de serina protease, processo de obtenção e uso para tratamento de flaviviroses

Publications (1)

Publication Number Publication Date
BRPI0401908A true BRPI0401908A (pt) 2006-01-17

Family

ID=35551003

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0401908 BRPI0401908A (pt) 2004-06-04 2004-06-04 Compostos inibidores de serina protease, processo de obtenção e uso para tratamento de flaviviroses

Country Status (1)

Country Link
BR (1) BRPI0401908A (pt)

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8541424B2 (en) 2008-12-23 2013-09-24 Abbott Laboratories Anti-viral compounds
US8686026B2 (en) 2010-06-10 2014-04-01 Abbvie Inc. Solid compositions
US8691938B2 (en) 2009-06-11 2014-04-08 Abbvie Inc. Anti-viral compounds
US8716454B2 (en) 2009-06-11 2014-05-06 Abbvie Inc. Solid compositions
US8937150B2 (en) 2009-06-11 2015-01-20 Abbvie Inc. Anti-viral compounds
US9034832B2 (en) 2011-12-29 2015-05-19 Abbvie Inc. Solid compositions
US9187496B2 (en) 2009-12-18 2015-11-17 Idenix Pharmaceuticals Llc 5,5-fused arylene or heteroarylene hepatitis C virus inhibitors
US9278922B2 (en) 2009-04-15 2016-03-08 Abbvie Inc. Anti-viral compounds
US9333204B2 (en) 2014-01-03 2016-05-10 Abbvie Inc. Solid antiviral dosage forms
US9394279B2 (en) 2009-06-11 2016-07-19 Abbvie Inc. Anti-viral compounds
US10201541B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
US11484534B2 (en) 2013-03-14 2022-11-01 Abbvie Inc. Methods for treating HCV

Cited By (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8541424B2 (en) 2008-12-23 2013-09-24 Abbott Laboratories Anti-viral compounds
US9278922B2 (en) 2009-04-15 2016-03-08 Abbvie Inc. Anti-viral compounds
US8921514B2 (en) 2009-06-11 2014-12-30 Abbvie Inc. Anti-viral compounds
US9394279B2 (en) 2009-06-11 2016-07-19 Abbvie Inc. Anti-viral compounds
US8691938B2 (en) 2009-06-11 2014-04-08 Abbvie Inc. Anti-viral compounds
US8937150B2 (en) 2009-06-11 2015-01-20 Abbvie Inc. Anti-viral compounds
US10039754B2 (en) 2009-06-11 2018-08-07 Abbvie Inc. Anti-viral compounds
US8716454B2 (en) 2009-06-11 2014-05-06 Abbvie Inc. Solid compositions
US10028937B2 (en) 2009-06-11 2018-07-24 Abbvie Inc. Anti-viral compounds
US9586978B2 (en) 2009-06-11 2017-03-07 Abbvie Inc. Anti-viral compounds
US9187496B2 (en) 2009-12-18 2015-11-17 Idenix Pharmaceuticals Llc 5,5-fused arylene or heteroarylene hepatitis C virus inhibitors
US8686026B2 (en) 2010-06-10 2014-04-01 Abbvie Inc. Solid compositions
US10201541B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
US9034832B2 (en) 2011-12-29 2015-05-19 Abbvie Inc. Solid compositions
US11484534B2 (en) 2013-03-14 2022-11-01 Abbvie Inc. Methods for treating HCV
US9333204B2 (en) 2014-01-03 2016-05-10 Abbvie Inc. Solid antiviral dosage forms
US9744170B2 (en) 2014-01-03 2017-08-29 Abbvie Inc. Solid antiviral dosage forms
US10105365B2 (en) 2014-01-03 2018-10-23 Abbvie Inc. Solid antiviral dosage forms

Similar Documents

Publication Publication Date Title
BRPI0401908A (pt) Compostos inibidores de serina protease, processo de obtenção e uso para tratamento de flaviviroses
ECSP045191A (es) "nuevos péptidos como inhibidores de la proteasa serina ns3 del virus de la hepatitis c"
BRPI0414176A (pt) inibidores de serina proteases, em particular hcv ns3-ns4a protease
DK1877435T3 (da) Glucagon-lignende peptid 2 (GLP-2)-analoger
CO5700785A2 (es) Composiciones inmunogenicas novedosas para la prevencion y el tratamiento de enfermedad meningococal
MXPA02006679A (es) Composicion farmaceutica.
BR0213817A (pt) Tratamento de sìndrome de resistência à insulina e diabete do tipo 2 com inibidores da pde9
ECSP034438A (es) Nuevos peptidos como inhibidores de ns-3-serina proteasa del virus de la hepatitis c
BR0112666A (pt) Peptìdeos como inibidores de ns3-serina protease de vìrus da hepatite c
SE0002202D0 (sv) New peptides
BR0308429A (pt) Aroilpiridinonas monocìclicas como agentes antiinflamatórios
BRPI0516825A (pt) inibição da protease ns3-ns4a do vìrus da hepatite c (vhc)
HN2002000275A (es) Derivados de 1,8 naftiridina y su uso para el tratamiento de diabetes y trastornos relacionados
BRPI0208183B8 (pt) peptídeo antígeno de câncer modificado por wt1 e vacinas para câncer
ATE544461T1 (de) Rekonstituierte tenside mit verbesserten eigenschaften
BRPI0407533A (pt) proteìnas de fusão e muteìnas do interferon alfa com propriedades melhoradas
DE60209152D1 (de) Pharmazeutische zusammensetzung, umfassend gabapentin oder ein analogon davon und ein alpha-aminoamid
BRPI0510526A (pt) formulações lìquidas estabilizadas de interferon
BR0310003A (pt) compostos peptìdeos e seu uso como substratos de protease
EA200900095A1 (ru) Лекарственные формы бифосфонатов для ингаляции и способы их применения
BRPI0415781A (pt) método para o tratamento de diabetes em um paciente e kit farmacêutico
DK1276763T3 (da) Anti-fryseproteiner, deres fremstilling og anvendelse
AR056137A1 (es) Un conjugado peptido inmunoglobulina y su uso como antiviral
WO2005002500A3 (en) Inhibitors of coronavirus
BR0005525A (pt) Inibidores de protease e seus usos farmacêuticos

Legal Events

Date Code Title Description
B03A Publication of an application: publication of a patent application or of a certificate of addition of invention
B06F Objections, documents and/or translations needed after an examination request according art. 34 industrial property law
B07D Technical examination (opinion) related to article 229 of industrial property law
B07E Notice of approval relating to section 229 industrial property law

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Technical examination (opinion): publication of technical examination (opinion)
B09B Decision: refusal
B09B Decision: refusal

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL